Dextenza is an intracanalicular insert that delivers a 0.4mg dose of dexamethasone, a corticosteroid, for up to 30 days following insertion.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ...

According to Singh, Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) reduces the amount of time ophthalmologists spend on patient education and follow-up, as well as time ...

BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that ...

The FDA has expanded the approval of Dextenza (dexamethasone ophthalmic insert) to include pediatric treatment.

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic ...